FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: hepatitis C

Sort
E.g., 2013-05-23
E.g., 2013-05-23
Enter a comma separated list of user names.

Medgenics' Receives Allowance for Key European Patent

Follows Similar U.S. Patent for Biopump Protein Therapy Technology and Expands Intellectual Property Portfolio

Medgenics has three long-acting protein therapy products in development based on this technology:

EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;

MDGN, Medgenics Inc.

** MDGN reported that it has received notice of ?Intention to Grant' from the European Patent Office for the patent application entitled ?USE OF DERMAL MICRO ORGANS,? with allowed claims covering a core element of its Biopump protein therapy technology.

Pages

ADVERTISE WITH US